tetradecanoylphorbol acetate has been researched along with cilnidipine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fukuda, N; Hu, WY; Kanmatsuse, K; Su, JZ | 1 |
Conrad, H; Essin, K; Gollasch, M; Haller, H; Hofmann, F; Huang, Y; Kirsch, T; Klugbauer, N; Litteral, J; Löhn, M; Luft, FC; Muzzulini, U; Tsang, SY; Waldron, P | 1 |
2 other study(ies) available for tetradecanoylphorbol acetate and cilnidipine
Article | Year |
---|---|
Effects of the L- and N-type calcium channel blocker cilnidipine on growth of vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Animals; Calcium Channel Blockers; Cell Division; Cells, Cultured; Culture Media, Serum-Free; Dihydropyridines; DNA; Fibroblast Growth Factor 2; Muscle, Smooth, Vascular; Nifedipine; Platelet-Derived Growth Factor; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetradecanoylphorbol Acetate; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2001 |
Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C.
Topics: Animals; Aorta; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Dihydropyridines; Electric Conductivity; Electrophysiology; Protein Isoforms; Protein Kinase C; Rats; Tetradecanoylphorbol Acetate; Vasoconstriction | 2002 |